ABOUT ANTENGENE MANAGEMENT TEAM SCIENTIFIC ADVISORY BOARD BOARD OF DIRECTORS INVESTORS

MANAGEMENT TEAM

Jay Mei, M.D., Ph.D.
Founder, Chairman and CEO

Dr. Mei has over 25 years of experience in clinical research and development of oncology therapeutics globally and has successfully led the development of multiple oncology products. He has published over 70 publications and holds multiple patents jointly with other inventors. In the 1990s, Dr. Mei dedicated himself to extensive cancer research at the National CancerInstitute in the United States. In 2001, Dr. Mei joined as a principal scientist in the oncology team in the drug discovery division and an associate director at Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. From 2006, Dr. Mei worked as a senior director at Novartis Oncology, part of the Innovative Medicines division of Novartis AG (a company listed on the SIX Swiss Exchange and the New York Stock Exchange with stock codes NOVN.SIX and NVS.NYSE, respectively). From 2008 to 2017, he served as an executive director of the clinical development department at Celgene (now part of Bristol-Myers Squibb (a company listed on the New York Stock Exchange with stock code BMY.NYSE)). Mei also currently holds adjunct professorship at the Baruch S. Blumberg Institute. Dr. Mei was involved in the management of Antengene since April 2017.

Prior to founding Antengene, Dr. Mei was a clinical research and development executive at Celgene. At Celgene, Dr. Mei was one of the leading members in the clinical development of multiple blockbuster drugs that represent the most significant part of Celgene’s portfolio today, including REVLIMID®, which is among the best-selling oncology therapies worldwide, and was also involved in the clinical development of POMALYST®, also one of the best-selling oncology drugs worldwide, and IDHIFA®, a first-in-class drug for the treatment of acute myeloid leukemia.

Dr. Mei received his Doctor of Medicine degree in medicine from Hunan Medical University (now XiangYa School of Medicine of Central South University and obtained his Doctor of Philosophy degree in pharmacology and toxicology from the University of Maryland. Dr. Mei was a member of the American Society of Clinical Oncology and has also been a member of the American Society of Hematology since 2006.

John F. Chin, MBA
Chief Business Officer

Mr. Chin has 30 years of experience in the pharmaceutical industry, including as the former Country General Manager at Celgene China, leading a cross-functional team to support the development, approval and commercialization of Celgene assets in China.

His involvement was instrumental in the commercial launch and lifecycle management of REVLIMID®, one of the industry’s most successful oncology products globally.

Donald Andrew Lung, J.D., MBA
Chief Financial Officer

Mr. Lung has more than 16 years of experience in investment banking and public equities, including at Goldman Sachs and BFAM Partners.

He invested across sectors, including in the healthcare and biotech industry at BFAM Partners.

Yiteng Liu, M.Sc.
Chief Operating Officer

Mr. Liu has over 10 years of experience in various capacities at multi-national companies in investment and industry consulting.

He led RMB2.5 billion investment in healthcare projects at CITIC Industrial Investment Group Corp., Ltd. while serving as the general manager of the strategic development department at CITIC Senior Living Ltd.

Yijun Yang, Ph.D., Sc.D.
Corporate Vice President, Alliance Management and Clinical Enabling Functions

Dr. Yang has 20 years of experience in the pharmaceutical industry and held positions at Harvard University and multiple global pharmaceutical companies.

He participated in the clinical development approvals of multiple therapeutics, including INCIVEK® (telaprevir), TORISEL® (temsirolimus) and KANUMA® (sebelipase alfa).

Zhinuan Yu, Ph.D.
Corporate Vice President, Biometrics & Regulatory Enabling Functions

Dr. Yu has over 20 years of experience in the pharmaceutical industry and led the statistical support at Celgene for multiple high-priority programs, including thalidomide, lenalidomide, pomalidomide and bb2121 (CAR-T).

She received John W. Jackson Leadership Award, the highest individual recognition bestowed by Celgene.

Thomas Karalis, B.Sc.
Corporate Vice President, Head of Asia Pacific Region

Mr. Karalis has over 30 years of experience in the pharmaceutical industry, including as the former General Manager for Celgene East Asia and Vice President & General Manager for Celgene Australia and New Zealand.

During his tenure at Celgene, multiple regulatory and reimbursement milestones were achieved for core products in APAC markets leading to successful launches of REVLIMID® (lenalidomide), POMALYST® (pomalidomide) and ABRAXANE® (paclitaxel protein-bound particles for injectable suspension).

Bo Shan, Ph.D.
Corporate Vice President, Discovery, Early Development and CMC

Dr. Shan has over 15 years of experience in R&D and manufacturing in the pharmaceutical industry.

He led and managed chemical, manufacturing and control (CMC) programs resulting in multiple NDA and ANDA filings.

He previously oversaw the construction and validation of Ascletis Pharma’s Shaoxing production facility as well as production, quality, sourcing, EHS and engineering departments.

Jasmine Sun, M.D., MPH
Corporate Vice President, Head of Clinical Operations

Ms. Sun has nearly 20 years of clinical development and clinical trial operations experience in different disease areas, especially in oncology and infectious diseases.

She participated, managed and led over 70 clinical trials across Phase I to Phase IV.

She involved in many important China registration projects, including HERCEPTIN®, PEGASYS®, PEGINTRON®, TARCEVA® and first rituximab biosimilar product in China.

Dirk Hoenemann, M.D.
Vice President, Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

Mr. Hoenemann has over 20 years of experience in clinical research, translational medicine, academia, and the pharmaceutical industry.

He published numerous journals and articles in relation to first-in-human initiatives with novel antibody formats in hematological malignancies and solid tumors.

He made substantial contributions to CAR-T study targeting Lewis-Y antigen.